We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Vascular Biogenics Ltd | NASDAQ:VBLT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.156 | 0.1598 | 0.1599 | 0 | 01:00:00 |
Conference Call and Webcast at 8:30am Eastern Time Today
“We continue to advance the OVAL trial, our Phase 3 potential registration trial in platinum-resistant ovarian cancer, in collaboration with the GOG Foundation,” said Yael Cohen M.D., VP Clinical Development of VBL Therapeutic. “We are in the process of amending the protocol to include an interim analysis for evidence of an early efficacy signal with a potential readout from this analysis in the fourth quarter of 2019.”
“We are also advancing our MOSPD2 program for oncology and inflammatory indications and, at the recent American Academy of Cancer Research (AACR) meeting, presented new proof-of-concept on the use of a bispecific antibody to kill MOSPD2-expressing cancer cells,” said Dror Harats M.D., Chief Executive Officer of VBL Therapeutics. “VBL is well capitalized, with approximately $50 million in cash, which will enable us to continue the development of VB-111 and our deep pipeline through 2020.’
First Quarter and Recent Corporate Highlights:
First Quarter Ended March 31, 2018 Financial Results:
Conference Call:
Thursday, May 17th @ 8:30am Eastern Time
US Domestic: | 877-222-6394 | |
International: | 1-703-925-2702 | |
Conference ID: | 9993639 | |
Webcast: | https://edge.media-server.com/m6/p/zja7xger |
Replays, Available through May 31, 2018
US Domestic: | 855-859-2056 | |
International: | 1-404-537-3406 | |
Conference ID: | 9993639 |
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >300 cancer patients and demonstrated efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 trial for platinum-resistant ovarian cancer.
Forward Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding VB-111, including its clinical development, therapeutic potential and clinical results. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and the risk that historical clinical trial results may not be predictive of future trial results. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the U.S. Securities and Exchange Commission, including in our annual report on Form 20-F for the year ended December 31, 2017. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
INVESTOR CONTACT:Michael RiceLifeSci Advisors, LLC(646) 597-6979
VASCULAR BIOGENICS LTD. | ||||||||||
CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION | ||||||||||
(UNAUDITED) | ||||||||||
March, 31 | December, 31 | |||||||||
2018 | 2017 | |||||||||
U.S. dollars in thousands | ||||||||||
Assets | ||||||||||
CURRENT ASSETS: | ||||||||||
Cash and cash equivalents | $ | 8,583 | $ | 6,694 | ||||||
Short-term bank deposits | 41,306 | 48,035 | ||||||||
Trade receivables | — | 2,000 | ||||||||
Other current assets | 2,307 | 1,729 | ||||||||
TOTAL CURRENT ASSETS | 52,196 | 58,458 | ||||||||
NON-CURRENT ASSETS: | ||||||||||
Property and equipment, net | 8,222 | 7,128 | ||||||||
Long-term prepaid expenses | 64 | 103 | ||||||||
TOTAL NON-CURRENT ASSETS | 8,286 | 7,231 | ||||||||
TOTAL ASSETS | $ | 60,482 | $ | 65,689 | ||||||
Liabilities and equity | ||||||||||
CURRENT LIABILITIES- | ||||||||||
Accounts payable: | ||||||||||
Trade | $ | 3,612 | $ | 3,058 | ||||||
Other | 3,426 | 3,465 | ||||||||
Deferred revenue | 883 | 1,046 | ||||||||
TOTAL CURRENT LIABILITIES | 7,921 | 7,569 | ||||||||
NON-CURRENT LIABILITIES- | ||||||||||
Severance pay obligations, net | 128 | 128 | ||||||||
Deferred revenue | 2,092 | 2,092 | ||||||||
TOTAL NON-CURRENT LIABILITIES | 2,220 | 2,220 | ||||||||
TOTAL LIABILITIES | 10,141 | 9,789 | ||||||||
EQUITY: | ||||||||||
Ordinary shares | 57 | 57 | ||||||||
Accumulated other comprehensive income | 16 | 16 | ||||||||
Additional paid in capital | 222,675 | 221,055 | ||||||||
Warrants | 2,960 | 2,960 | ||||||||
Accumulated deficit | (175,367 | ) | (168,188 | ) | ||||||
TOTAL EQUITY | 50,341 | 55,900 | ||||||||
TOTAL LIABILITIES AND EQUITY | $ | 60,482 | $ | 65,689 |
VASCULAR BIOGENICS LTD. | ||||||||||||||||||||
CONDENSED INTERIM STATEMENTS OF COMPREHENSIVE LOSS | ||||||||||||||||||||
(UNAUDITED) | ||||||||||||||||||||
Three Months Ended March 31, | ||||||||||||||||||||
2018 | 2017 | |||||||||||||||||||
U.S. dollars in thousands | ||||||||||||||||||||
REVENUES | 163 | - | ||||||||||||||||||
COST OF REVENUES | (67 | ) | - | |||||||||||||||||
GROSS PROFIT | 96 | - | ||||||||||||||||||
RESEARCH AND DEVELOPMENT EXPENSES, net | $ | 5,760 | $ | 4,144 | ||||||||||||||||
MARKETING EXPENSES | 235 | - | ||||||||||||||||||
GENERAL AND ADMINISTRATIVE EXPENSES | 1,395 | 1,105 | ||||||||||||||||||
OPERATING LOSS | 7,294 | 5,249 | ||||||||||||||||||
FINANCIAL INCOME | (145 | ) | (219 | ) | ||||||||||||||||
FINANCIAL EXPENSES | 30 | 4 | ||||||||||||||||||
FINANCIAL EXPENSES (INCOME), net | (115 | ) | (215 | ) | ||||||||||||||||
COMPREHENSIVE LOSS | 7,179 | 5,034 | ||||||||||||||||||
LOSS PER ORDINARY SHARE | ||||||||||||||||||||
Basic and diluted | $ | 0.24 | $ | 0.19 | ||||||||||||||||
Number of shares | ||||||||||||||||||||
WEIGHTED AVERAGE ORDINARY SHARES OUTSTANDING- | ||||||||||||||||||||
Basic and diluted | 29,887,254 | 26,907,172 |
1 Year Vascular Biogenics Chart |
1 Month Vascular Biogenics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions